Key Highlights

  • H1 2026 Revenue rose 23% to £95.2m and adjusted profit before tax rose 34% to £15.3m.
  • Margins expanded, with gross Margin up ~100bps to 35.6% and adjusted Operating Margin up ~130bps to 17.1%.
  • Aerospace, transport and geographic growth offset a ~23% fall in footwear revenue.
  • Net Debt was £39.1m (leverage ~0.98x); a new £90m revolving Credit Facility was put in place and the Interim Dividend rose 5.2% to 2.63p.
  • FY2026 guidance was unchanged and the FY2029 targets of £230m+ revenue and £40m+ operating profit were reaffirmed.

Zotefoams (LSE:ZTF) is a rare thing on the London market: a genuinely differentiated materials Business built on nitrogen-expanded cellular foams that show up in everything from trainers and aircraft interiors to medical devices and industrial insulation. For years the Investment debate has centred on whether the company can convert its technology edge and capacity investment into consistent, diversified growth rather than lumpy, single-market swings.

The half-year results to 30 June 2026, published on 5 August 2026, offered supportive evidence. Group revenue rose 23% to £95.2 million and adjusted profit before tax jumped 34% to £15.3 million, with margins expanding even as the once red-hot footwear business normalised sharply. Management framed the outcome as proof of a 'broader and more balanced' company.

Latest Development

The standout feature of the first half was the breadth of growth. On a geographic basis, EMEA revenue rose about 20% to £73.6 million — helped by roughly £14.8 million contributed by the OKC Acquisition — while North America grew about 29% to £18.7 million and Asia more than doubled to £2.9 million. Aerospace wins and Demand for transport and smart-technology applications underpinned the momentum.

Crucially, this strength came despite footwear revenue falling around 23% as post-boom demand normalised. Zotefoams is managing that transition by shifting footwear production towards Vietnam and developing 3D preform technology. That the group could still post 23% headline growth while its highest-profile end market contracted is the clearest signal yet that Diversification is working.

The Numbers

Profitability improved on every measure investors typically track. Adjusted operating profit rose 34% to £16.3 million, statutory profit before tax rose 23% to £14.0 million, and adjusted Earnings Per Share increased 29% to 25.70p. Gross margin improved about 100 basis points to 35.6%, and the adjusted operating margin rose roughly 130 basis points to 17.1%, indicating the growth is translating into operational Leverage rather than being bought with margin.

On the balance sheet, net debt stood at £39.1 million, equating to leverage of about 0.98 times, and the company put in place a new £90 million revolving credit facility, giving it headroom to fund capacity and acquisitions. The board raised the interim dividend 5.2% to 2.63p.

The Investment Story

Zotefoams' appeal lies in proprietary, high-value materials sold into markets with structural tailwinds. Its high-performance ZOTEK foams serve aviation, where fire, smoke and toxicity performance commands a premium; its T-FIT insulation targets industrial and life-sciences applications; and its polyolefin foams Supply protective packaging, sport and construction. The footwear franchise, though cyclical, links the group to global sportswear brands.

The longer-term optionality sits in ReZorce, a mono-material recyclable barrier packaging technology aimed at replacing hard-to-recycle multi-layer cartons. If commercialised at scale, it could open a large addressable market in food and beverage packaging. For now it remains a development and licensing opportunity rather than a material earnings contributor, so the core investment case still rests on the established foams and insulation businesses and the capacity being added to serve them.

What Could Drive the Shares?

Continued conversion of aerospace and transport wins into revenue, alongside a recovery or stabilisation in footwear, would support the diversified-growth narrative and the FY2029 targets. Evidence that new and acquired capacity is being filled at healthy margins could reinforce confidence in the operating-leverage story.

Progress on ReZorce — new customer trials, licensing deals or commercial contracts — could add an entirely new dimension to the valuation, though investors should treat it as optionality rather than a certainty. Sustained margin expansion and disciplined use of the new credit facility for value-accretive investment would also help sentiment.

Risks Investors Should Watch

Footwear remains a swing factor: the first-half decline shows how quickly a major end market can reverse, and the transition to Vietnam and 3D preforms carries execution risk. The reliance on acquisitions such as OKC to bolster reported growth means organic growth — reported at a more modest single-digit rate — deserves scrutiny.

Net debt of £39.1 million and leverage near one times are manageable but leave less room for error if demand softens or capacity investment runs ahead of orders. As a specialty manufacturer, Zotefoams is exposed to raw-material and energy costs, currency movements across its international footprint, and the pace at which longer-dated bets like ReZorce convert into revenue.

What Happens Next?

The next scheduled checkpoint is full-year 2026 results, where investors will look for confirmation that footwear has stabilised, that aerospace and geographic growth has been sustained into the second half, and that margins have held. Updates on capacity utilisation across the US, Poland and Asia plants will indicate how efficiently the group is absorbing its investment.

Beyond the numbers, commentary on ReZorce commercialisation, any further bolt-on acquisitions, and progress towards the FY2029 revenue and profit targets will shape the medium-term view. The trajectory of footwear demand and the ramp of the Vietnam supply chain will be closely followed.

Bottom Line

Zotefoams (LSE:ZTF) delivered a confident first half, growing revenue 23% and adjusted profit 34% while expanding margins and lifting the dividend, all despite a sharp footwear slowdown. The bull case is a diversifying, technology-led materials group with aerospace, insulation and packaging optionality and a clear path towards its FY2029 targets. The risks are a still-cyclical footwear business, a reliance on acquisitions to flatter headline growth, and modest leverage that limits room for missteps. The central question is whether Zotefoams' broadening end-market base can keep delivering steady growth through the footwear normalisation.